Literature DB >> 26892983

Autoimmune Comorbidities Are Associated with Brain Injury in Multiple Sclerosis.

R Zivadinov1, B Raj2, M Ramanathan3, B Teter4, J Durfee2, M G Dwyer2, N Bergsland5, C Kolb4, D Hojnacki4, R H Benedict4, B Weinstock-Guttman4.   

Abstract

BACKGROUND AND
PURPOSE: The effect of comorbidities on disease severity in MS has not been extensively characterized. We determined the association of comorbidities with MR imaging disease severity outcomes in MS.
MATERIALS AND METHODS: Demographic and clinical history of 9 autoimmune comorbidities confirmed by retrospective chart review and quantitative MR imaging data were obtained in 815 patients with MS. The patients were categorized on the basis of the presence/absence of total and specific comorbidities. We analyzed the MR imaging findings, adjusting for key covariates and correcting for multiple comparisons.
RESULTS: Two hundred forty-one (29.6%) study subjects presented with comorbidities. Thyroid disease had the highest frequency (n = 97, 11.9%), followed by asthma (n = 41, 5%), type 2 diabetes mellitus (n = 40, 4.9%), psoriasis (n = 33, 4%), and rheumatoid arthritis (n = 22, 2.7%). Patients with MS with comorbidities showed decreased whole-brain and cortical volumes (P < .001), gray matter volume and magnetization transfer ratio of normal-appearing brain tissue (P < .01), and magnetization transfer ratio of gray matter (P < .05). Psoriasis, thyroid disease, and type 2 diabetes mellitus comorbidities were associated with decreased whole-brain, cortical, and gray matter volumes (P < .05). Psoriasis was associated with a decreased magnetization transfer ratio of normal-appearing brain tissue (P < .05), while type 2 diabetes mellitus was associated with increased mean diffusivity (P < .01).
CONCLUSIONS: The presence of comorbidities in patients with MS is associated with brain injury on MR imaging. Psoriasis, thyroid disease, and type 2 diabetes mellitus comorbidities were associated with more severe nonconventional MR imaging outcomes.
© 2016 by American Journal of Neuroradiology.

Entities:  

Mesh:

Year:  2016        PMID: 26892983      PMCID: PMC7963547          DOI: 10.3174/ajnr.A4681

Source DB:  PubMed          Journal:  AJNR Am J Neuroradiol        ISSN: 0195-6108            Impact factor:   3.825


  39 in total

1.  Coincidence of immune-mediated diseases driven by Th1 and Th2 subsets suggests a common aetiology. A population-based study using computerized general practice data.

Authors:  C R Simpson; W J A Anderson; P J Helms; M W Taylor; L Watson; G J Prescott; D J Godden; R N Barker
Journal:  Clin Exp Allergy       Date:  2002-01       Impact factor: 5.018

2.  Effects of IV methylprednisolone on brain atrophy in relapsing-remitting MS.

Authors:  R Zivadinov; R A Rudick; R De Masi; D Nasuelli; M Ukmar; R S Pozzi-Mucelli; A Grop; G Cazzato; M Zorzon
Journal:  Neurology       Date:  2001-10-09       Impact factor: 9.910

3.  Patients with multiple sclerosis and risk of type 1 diabetes mellitus in Sardinia, Italy: a cohort study.

Authors:  Maria Giovanna Marrosu; Eleonora Cocco; Marina Lai; Gabriella Spinicci; Maria Paola Pischedda; Paolo Contu
Journal:  Lancet       Date:  2002-04-27       Impact factor: 79.321

4.  Abnormal subcortical deep-gray matter susceptibility-weighted imaging filtered phase measurements in patients with multiple sclerosis: a case-control study.

Authors:  Robert Zivadinov; Mari Heininen-Brown; Claudiu V Schirda; Guy U Poloni; Niels Bergsland; Christopher R Magnano; Jacqueline Durfee; Cheryl Kennedy; Ellen Carl; Jesper Hagemeier; Ralph H B Benedict; Bianca Weinstock-Guttman; Michael G Dwyer
Journal:  Neuroimage       Date:  2011-07-27       Impact factor: 6.556

5.  Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis.

Authors:  Robert J Fox; David H Miller; J Theodore Phillips; Michael Hutchinson; Eva Havrdova; Mariko Kita; Minhua Yang; Kartik Raghupathi; Mark Novas; Marianne T Sweetser; Vissia Viglietta; Katherine T Dawson
Journal:  N Engl J Med       Date:  2012-09-20       Impact factor: 91.245

6.  Lipid profiles are associated with lesion formation over 24 months in interferon-β treated patients following the first demyelinating event.

Authors:  Bianca Weinstock-Guttman; Robert Zivadinov; Dana Horakova; Eva Havrdova; Jun Qu; Grace Shyh; Elizabeth Lakota; Kerri O'Connor; Darlene Badgett; Miriam Tamaño-Blanco; Michaela Tyblova; Sara Hussein; Niels Bergsland; Laura Willis; Jan Krasensky; Manuela Vaneckova; Zdenek Seidl; Murali Ramanathan
Journal:  J Neurol Neurosurg Psychiatry       Date:  2013-04-17       Impact factor: 10.154

7.  A prospective study of conditions associated with multiple sclerosis in a cohort of 658 consecutive outpatients attending a multiple sclerosis clinic.

Authors:  L J Edwards; C S Constantinescu
Journal:  Mult Scler       Date:  2004-10       Impact factor: 6.312

8.  Multiple sclerosis characteristics in African American patients in the New York State Multiple Sclerosis Consortium.

Authors:  B Weinstock-Guttman; L D Jacobs; C M Brownscheidle; M Baier; D F Rea; B R Apatoff; K M Blitz; P K Coyle; A T Frontera; A D Goodman; M H Gottesman; J Herbert; R Holub; N S Lava; M Lenihan; J Lusins; C Mihai; A E Miller; A B Perel; D H Snyder; R Bakshi; C V Granger; S J Greenberg; B Jubelt; L Krupp; F E Munschauer; D Rubin; S Schwid; J Smiroldo
Journal:  Mult Scler       Date:  2003-06       Impact factor: 6.312

Review 9.  Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria".

Authors:  Chris H Polman; Stephen C Reingold; Gilles Edan; Massimo Filippi; Hans-Peter Hartung; Ludwig Kappos; Fred D Lublin; Luanne M Metz; Henry F McFarland; Paul W O'Connor; Magnhild Sandberg-Wollheim; Alan J Thompson; Brian G Weinshenker; Jerry S Wolinsky
Journal:  Ann Neurol       Date:  2005-12       Impact factor: 10.422

Review 10.  A systematic review of the incidence and prevalence of sleep disorders and seizure disorders in multiple sclerosis.

Authors:  Ruth Ann Marrie; Nadia Reider; Jeffrey Cohen; Maria Trojano; Per Soelberg Sorensen; Gary Cutter; Stephen Reingold; Olaf Stuve
Journal:  Mult Scler       Date:  2014-12-22       Impact factor: 6.312

View more
  8 in total

1.  Autoimmune comorbidities in multiple sclerosis: what is the influence on brain volumes? A case-control MRI study.

Authors:  Lorena Lorefice; Giuseppe Fenu; Roberta Pitzalis; Giulia Scalas; Jessica Frau; Giancarlo Coghe; Luigina Musu; Vincenzo Sechi; Maria Antonietta Barracciu; Maria Giovanna Marrosu; Eleonora Cocco
Journal:  J Neurol       Date:  2018-03-05       Impact factor: 4.849

2.  Abnormal venous postural control: multiple sclerosis-specific change related to gray matter pathology or age-related neurodegenerative phenomena?

Authors:  Dejan Jakimovski; Matthew Topolski; Kana Kimura; Karen Marr; Sirin Gandhi; Deepa P Ramasamy; Niels Bergsland; Jesper Hagemeier; Bianca Weinstock-Guttman; Robert Zivadinov
Journal:  Clin Auton Res       Date:  2018-08-17       Impact factor: 4.435

Review 3.  Comorbidity in multiple sclerosis: implications for patient care.

Authors:  Ruth Ann Marrie
Journal:  Nat Rev Neurol       Date:  2017-03-17       Impact factor: 42.937

Review 4.  Quantitative magnetization transfer imaging in relapsing-remitting multiple sclerosis: a systematic review and meta-analysis.

Authors:  Elizabeth N York; Michael J Thrippleton; Rozanna Meijboom; David P J Hunt; Adam D Waldman
Journal:  Brain Commun       Date:  2022-04-04

5.  A Case of Seronegative Limbic Encephalitis with Multiple Sclerosis: A Possible Overlapping Syndrome.

Authors:  Zerrin Karaaslan; Özlem Mercan; Erdem Tüzün; Handan Mısırlı; Recai Türkoğlu
Journal:  Am J Case Rep       Date:  2017-01-18

Review 6.  Detecting neurodegenerative pathology in multiple sclerosis before irreversible brain tissue loss sets in.

Authors:  Jeroen Van Schependom; Kaat Guldolf; Marie Béatrice D'hooghe; Guy Nagels; Miguel D'haeseleer
Journal:  Transl Neurodegener       Date:  2019-12-09       Impact factor: 8.014

Review 7.  Measuring Treatment Response in Progressive Multiple Sclerosis-Considerations for Adapting to an Era of Multiple Treatment Options.

Authors:  Nik Krajnc; Thomas Berger; Gabriel Bsteh
Journal:  Biomolecules       Date:  2021-09-10

Review 8.  A global view of comorbidity in multiple sclerosis: a systematic review with a focus on regional differences, methodology, and clinical implications.

Authors:  Larissa Hauer; Julian Perneczky; Johann Sellner
Journal:  J Neurol       Date:  2020-07-27       Impact factor: 4.849

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.